Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Helen MossopMichael John GraylingFerdia A GallagherSarah J WelshGrant D StewartJames M S WasonPublished in: British journal of cancer (2021)
We recommend the MASTER design as an efficient way of testing multiple promising cancer treatments in non-comparative Phase II trials.